China · Delayed Price · Currency is CNY Guanhao Biotech Statistics
Total Valuation
Guanhao Biotech has a market cap or net worth of CNY 3.97 billion. The enterprise value is 3.86 billion.
| Market Cap | 3.97B |
| Enterprise Value | 3.86B |
Important Dates
The last earnings date was Thursday, March 26, 2026.
| Earnings Date | Mar 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Guanhao Biotech has 265.16 million shares outstanding. The number of shares has decreased by -1.33% in one year.
| Current Share Class | 265.16M |
| Shares Outstanding | 265.16M |
| Shares Change (YoY) | -1.33% |
| Shares Change (QoQ) | -3.76% |
| Owned by Insiders (%) | 1.87% |
| Owned by Institutions (%) | 6.58% |
| Float | 199.79M |
Valuation Ratios
The trailing PE ratio is 166.56.
| PE Ratio | 166.56 |
| Forward PE | n/a |
| PS Ratio | 10.25 |
| PB Ratio | 8.15 |
| P/TBV Ratio | 7.98 |
| P/FCF Ratio | 119.35 |
| P/OCF Ratio | 55.61 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 67.63, with an EV/FCF ratio of 115.87.
| EV / Earnings | 158.50 |
| EV / Sales | 9.95 |
| EV / EBITDA | 67.63 |
| EV / EBIT | 109.83 |
| EV / FCF | 115.87 |
Financial Position
The company has a current ratio of 1.73, with a Debt / Equity ratio of 0.26.
| Current Ratio | 1.73 |
| Quick Ratio | 1.15 |
| Debt / Equity | 0.26 |
| Debt / EBITDA | 2.22 |
| Debt / FCF | 3.81 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 3.10% and return on invested capital (ROIC) is 4.11%.
| Return on Equity (ROE) | 3.10% |
| Return on Assets (ROA) | 2.81% |
| Return on Invested Capital (ROIC) | 4.11% |
| Return on Capital Employed (ROCE) | 5.69% |
| Weighted Average Cost of Capital (WACC) | 5.89% |
| Revenue Per Employee | 731,603 |
| Profits Per Employee | 45,936 |
| Employee Count | 530 |
| Asset Turnover | 0.50 |
| Inventory Turnover | 1.14 |
Taxes
In the past 12 months, Guanhao Biotech has paid 12.49 million in taxes.
| Income Tax | 12.49M |
| Effective Tax Rate | 45.80% |
Stock Price Statistics
The stock price has increased by +10.46% in the last 52 weeks. The beta is 0.33, so Guanhao Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | +10.46% |
| 50-Day Moving Average | 15.99 |
| 200-Day Moving Average | 16.01 |
| Relative Strength Index (RSI) | 45.05 |
| Average Volume (20 Days) | 8,658,835 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Guanhao Biotech had revenue of CNY 387.75 million and earned 24.35 million in profits. Earnings per share was 0.09.
| Revenue | 387.75M |
| Gross Profit | 299.08M |
| Operating Income | 35.13M |
| Pretax Income | 27.28M |
| Net Income | 24.35M |
| EBITDA | 56.01M |
| EBIT | 35.13M |
| Earnings Per Share (EPS) | 0.09 |
Balance Sheet
The company has 160.60 million in cash and 126.93 million in debt, with a net cash position of 33.68 million or 0.13 per share.
| Cash & Cash Equivalents | 160.60M |
| Total Debt | 126.93M |
| Net Cash | 33.68M |
| Net Cash Per Share | 0.13 |
| Equity (Book Value) | 487.82M |
| Book Value Per Share | 2.03 |
| Working Capital | 137.07M |
Cash Flow
In the last 12 months, operating cash flow was 71.47 million and capital expenditures -38.17 million, giving a free cash flow of 33.30 million.
| Operating Cash Flow | 71.47M |
| Capital Expenditures | -38.17M |
| Depreciation & Amortization | 20.88M |
| Net Borrowing | 25.00M |
| Free Cash Flow | 33.30M |
| FCF Per Share | 0.13 |
Margins
Gross margin is 77.13%, with operating and profit margins of 9.06% and 6.28%.
| Gross Margin | 77.13% |
| Operating Margin | 9.06% |
| Pretax Margin | 7.04% |
| Profit Margin | 6.28% |
| EBITDA Margin | 14.45% |
| EBIT Margin | 9.06% |
| FCF Margin | 8.59% |
Dividends & Yields
Guanhao Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 15.07% |
| Buyback Yield | 1.33% |
| Shareholder Yield | 1.33% |
| Earnings Yield | 0.61% |
| FCF Yield | 0.84% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 16, 2015. It was a forward split with a ratio of 2.
| Last Split Date | Apr 16, 2015 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |